#62 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Children with drug-resistant epilepsy whose families cannot afford private prescriptions may continue to go without a treatment option that has demonstrated clinical evidence, simply because NHS commissioning has not kept pace with the legal changes already on the books.
Drug-resistant epilepsy in children, particularly conditions like Dravet syndrome and Lennox-Gastaut syndrome, represents one of the most compelling and well-documented areas for cannabinoid-based medicine, with cannabidiol demonstrating meaningful seizure reduction in controlled clinical trials. Despite the rescheduling of cannabis-based medicines in the UK following high-profile advocacy, NHS access remains severely limited by prescribing restrictions, funding barriers, and a shortage of specialists willing to initiate treatment. Families continue to face a fragmented system where a legal pathway exists on paper but functional access remains out of reach for many children who have exhausted conventional antiseizure medications.
“When a government reschedules a medicine in response to a child’s suffering and then fails to fund access to that same medicine, the rescheduling was symbolism, not policy.”
The persistent gap between legal access and clinical availability of cannabis-derived medicines for drug-resistant epilepsy in children represents a significant unmet medical need in the UK. While the 2018 policy change established the legal framework for prescribing, the stringent NHS commissioning criteria and limited NHS-funded pathways have created a situation where evidence-based treatment remains inaccessible to many families despite demonstrated efficacy in published trials. Children with refractory seizure disorders who have exhausted conventional antiepileptic options deserve timely evaluation for cannabinoid therapy, particularly given the favorable safety profile and mechanism of action distinct from traditional medications. Advocacy efforts highlighting individual cases serve an important function in bringing clinical realities to policymakers’ attention, ultimately benefiting pediatric patients who could benefit from this therapeutic option.
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it: